India
· Delayed Price · Currency is INR NATCO Pharma Statistics
Total Valuation
NATCO Pharma has a market cap or net worth of INR 157.40 billion. The enterprise value is 131.08 billion.
| Market Cap | 157.40B |
| Enterprise Value | 131.08B |
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | Feb 18, 2025 |
Share Statistics
NATCO Pharma has 179.11 million shares outstanding. The number of shares has decreased by -0.21% in one year.
| Current Share Class | 179.11M |
| Shares Outstanding | 179.11M |
| Shares Change (YoY) | -0.21% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 13.93% |
| Owned by Institutions (%) | 17.41% |
| Float | 112.10M |
Valuation Ratios
The trailing PE ratio is 8.35 and the forward PE ratio is 12.40.
| PE Ratio | 8.35 |
| Forward PE | 12.40 |
| PS Ratio | 3.55 |
| PB Ratio | 2.07 |
| P/TBV Ratio | 2.14 |
| P/FCF Ratio | 12.15 |
| P/OCF Ratio | 9.28 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.97, with an EV/FCF ratio of 10.12.
| EV / Earnings | 6.95 |
| EV / Sales | 2.96 |
| EV / EBITDA | 5.97 |
| EV / EBIT | 6.68 |
| EV / FCF | 10.12 |
Financial Position
The company has a current ratio of 5.59, with a Debt / Equity ratio of 0.04.
| Current Ratio | 5.59 |
| Quick Ratio | 3.97 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.13 |
| Debt / FCF | 0.22 |
| Interest Coverage | 82.04 |
Financial Efficiency
Return on equity (ROE) is 27.97% and return on invested capital (ROIC) is 17.34%.
| Return on Equity (ROE) | 27.97% |
| Return on Assets (ROA) | 15.78% |
| Return on Invested Capital (ROIC) | 17.34% |
| Return on Capital Employed (ROCE) | 25.51% |
| Revenue Per Employee | 11.03M |
| Profits Per Employee | 4.69M |
| Employee Count | 4,016 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 0.89 |
Taxes
In the past 12 months, NATCO Pharma has paid 4.08 billion in taxes.
| Income Tax | 4.08B |
| Effective Tax Rate | 17.81% |
Stock Price Statistics
The stock price has decreased by -27.02% in the last 52 weeks. The beta is 0.31, so NATCO Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | -27.02% |
| 50-Day Moving Average | 863.24 |
| 200-Day Moving Average | 1,136.89 |
| Relative Strength Index (RSI) | 48.39 |
| Average Volume (20 Days) | 830,957 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NATCO Pharma had revenue of INR 44.30 billion and earned 18.85 billion in profits. Earnings per share was 105.26.
| Revenue | 44.30B |
| Gross Profit | 37.40B |
| Operating Income | 19.61B |
| Pretax Income | 22.91B |
| Net Income | 18.85B |
| EBITDA | 21.96B |
| EBIT | 19.61B |
| Earnings Per Share (EPS) | 105.26 |
Balance Sheet
The company has 24.97 billion in cash and 2.79 billion in debt, giving a net cash position of 22.17 billion or 123.80 per share.
| Cash & Cash Equivalents | 24.97B |
| Total Debt | 2.79B |
| Net Cash | 22.17B |
| Net Cash Per Share | 123.80 |
| Equity (Book Value) | 76.12B |
| Book Value Per Share | 424.69 |
| Working Capital | 43.27B |
Cash Flow
In the last 12 months, operating cash flow was 16.97 billion and capital expenditures -4.01 billion, giving a free cash flow of 12.96 billion.
| Operating Cash Flow | 16.97B |
| Capital Expenditures | -4.01B |
| Free Cash Flow | 12.96B |
| FCF Per Share | 72.34 |
Margins
Gross margin is 84.43%, with operating and profit margins of 44.27% and 42.56%.
| Gross Margin | 84.43% |
| Operating Margin | 44.27% |
| Pretax Margin | 51.73% |
| Profit Margin | 42.56% |
| EBITDA Margin | 49.58% |
| EBIT Margin | 44.27% |
| FCF Margin | 29.25% |
Dividends & Yields
This stock pays an annual dividend of 6.00, which amounts to a dividend yield of 0.68%.
| Dividend Per Share | 6.00 |
| Dividend Yield | 0.68% |
| Dividend Growth (YoY) | -36.84% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 5.72% |
| Buyback Yield | 0.21% |
| Shareholder Yield | 0.90% |
| Earnings Yield | 11.98% |
| FCF Yield | 8.23% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 26, 2015. It was a forward split with a ratio of 5.
| Last Split Date | Nov 26, 2015 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |